[go: up one dir, main page]

DOP2000000109A - Derivados de tiazolilamida - Google Patents

Derivados de tiazolilamida

Info

Publication number
DOP2000000109A
DOP2000000109A DO2000000109A DO2000000109A DOP2000000109A DO P2000000109 A DOP2000000109 A DO P2000000109A DO 2000000109 A DO2000000109 A DO 2000000109A DO 2000000109 A DO2000000109 A DO 2000000109A DO P2000000109 A DOP2000000109 A DO P2000000109A
Authority
DO
Dominican Republic
Prior art keywords
thiazolilamide
derivatives
medicaments
preparation
well
Prior art date
Application number
DO2000000109A
Other languages
English (en)
Inventor
Kerstin Henninger
Martin Hendrix
Olaf Weber
Geral Kleymann
Ruediger Fischer
Ulrich Betz
Judith Baumeister
Wolfgang Bender
Peter Eckenberg
Gabriele Handke
Axel Jensen
Joerg Keldenich
Udo Schneider
Original Assignee
Gerald Kleymann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19962532A external-priority patent/DE19962532A1/de
Priority claimed from DE10039265A external-priority patent/DE10039265A1/de
Application filed by Gerald Kleymann filed Critical Gerald Kleymann
Publication of DOP2000000109A publication Critical patent/DOP2000000109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a un procedimiento para su preparación así como a su uso como medicamentos, especialmente como medicamentos antivíricos
DO2000000109A 1999-12-23 2000-12-05 Derivados de tiazolilamida DOP2000000109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962532A DE19962532A1 (de) 1999-12-23 1999-12-23 Thiazolylamid-Derivate
DE10039265A DE10039265A1 (de) 2000-08-11 2000-08-11 Thiazolylamid-Derivate

Publications (1)

Publication Number Publication Date
DOP2000000109A true DOP2000000109A (es) 2002-08-30

Family

ID=26006669

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2000000109A DOP2000000109A (es) 1999-12-23 2000-12-05 Derivados de tiazolilamida

Country Status (26)

Country Link
US (1) US7105553B2 (es)
EP (1) EP1244641B1 (es)
JP (1) JP4726175B2 (es)
KR (1) KR100768361B1 (es)
CN (1) CN1235890C (es)
AR (1) AR029210A1 (es)
AT (1) ATE293104T1 (es)
AU (1) AU784286B2 (es)
BR (1) BR0017030B8 (es)
CA (1) CA2396720C (es)
CO (1) CO5261491A1 (es)
DE (1) DE50010060D1 (es)
DK (1) DK1244641T3 (es)
DO (1) DOP2000000109A (es)
ES (1) ES2240233T3 (es)
IL (2) IL149897A0 (es)
MX (1) MXPA02006243A (es)
MY (1) MY134880A (es)
NZ (1) NZ519701A (es)
PE (1) PE20010964A1 (es)
PL (1) PL208707B1 (es)
PT (1) PT1244641E (es)
SV (1) SV2002000249A (es)
TW (1) TWI256951B (es)
UY (1) UY26495A1 (es)
WO (1) WO2001047904A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412720A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
DK1789084T3 (da) * 2004-09-09 2011-01-10 Novartis Vaccines & Diagnostic Nedsættelse af potentiellle iatrogene risici forbundet med influenzavacciner
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
WO2007130075A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
CA2620878A1 (en) * 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
KR20150091427A (ko) * 2006-03-17 2015-08-10 더 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
US20100051879A1 (en) * 2006-11-22 2010-03-04 The Regents od the Univesity of California Functionalized Boron Nitride Nanotubes
EP2573086A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
MX2015010339A (es) * 2013-02-12 2015-11-16 Aicuris Gmbh & Co Kg Inhibidores de helicasa-primasa para su uso en un metodo para tratar la enfermedad de alzheimer.
MX392650B (es) * 2014-07-07 2025-03-24 Elian Llc Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion
US10590094B2 (en) * 2016-04-06 2020-03-17 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
CN110062755B (zh) 2016-11-28 2023-08-29 艾库里斯有限及两合公司 普瑞利韦的游离碱的马来酸盐、其药物制剂、其制造方法及其用于治疗疱疹病毒的用途
LT3544976T (lt) * 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
TW201825095A (zh) 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
JP7150343B2 (ja) * 2017-01-09 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール誘導体およびその使用
DK3692039T3 (da) 2017-10-05 2023-03-13 Innovative Molecules Gmbh Enantiomerer af substituerede thiazoler som antivirale forbindelser
US11964969B2 (en) 2018-07-06 2024-04-23 Phaeno Therapeutics Co., Ltd Crystal forms of thiazole compound and application thereof
CA3168721A1 (en) 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4237414A1 (en) 2020-10-29 2023-09-06 Innovative Molecules GmbH Deuterated aminothiazole compounds as antiviral compounds
IL314188A (en) 2022-01-17 2024-09-01 Innovative Molecules Gmbh Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
KR20250054809A (ko) 2022-08-29 2025-04-23 어셈블리 바이오사이언시스, 인크. Hsv 치료용 환식 우레아 티아졸릴 화합물
EP4581030A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
AU2023332667A1 (en) 2022-08-29 2025-03-13 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024224304A1 (en) 2023-04-26 2024-10-31 Assembly Biosciences, Inc. Oral pharmaceutical compositions
WO2025046457A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025046456A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025111598A1 (en) 2023-11-22 2025-05-30 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2075560A5 (es) 1970-01-16 1971-10-08 Shell Int Research
US3658830A (en) 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3717651A (en) 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
US3847588A (en) 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
DK0871619T3 (da) 1995-12-29 2003-03-03 Boehringer Ingelheim Pharma Phenylthiazolderivater med antiherpesvirusegenskaber
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
NZ507032A (en) 1998-03-19 2003-06-30 Pharmacia & Upjohn 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections
AU2914200A (en) 1999-03-08 2000-09-28 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents

Also Published As

Publication number Publication date
WO2001047904A1 (de) 2001-07-05
PL208707B1 (pl) 2011-05-31
US20040006076A1 (en) 2004-01-08
CN1434812A (zh) 2003-08-06
AU784286B2 (en) 2006-03-02
KR100768361B1 (ko) 2007-10-18
IL149897A (en) 2008-08-07
MXPA02006243A (es) 2003-01-28
JP4726175B2 (ja) 2011-07-20
DK1244641T3 (da) 2005-07-11
US7105553B2 (en) 2006-09-12
NZ519701A (en) 2004-05-28
CO5261491A1 (es) 2003-03-31
AR029210A1 (es) 2003-06-18
JP2003519134A (ja) 2003-06-17
PE20010964A1 (es) 2001-11-10
HK1057552A1 (en) 2004-04-08
SV2002000249A (es) 2002-06-07
IL149897A0 (en) 2002-11-10
MY134880A (en) 2007-12-31
AU3157401A (en) 2001-07-09
CA2396720C (en) 2009-09-22
CN1235890C (zh) 2006-01-11
KR20020067568A (ko) 2002-08-22
EP1244641A1 (de) 2002-10-02
UY26495A1 (es) 2001-07-31
TWI256951B (en) 2006-06-21
CA2396720A1 (en) 2001-07-05
ES2240233T3 (es) 2005-10-16
BR0017030B1 (pt) 2013-10-01
BR0017030A (pt) 2003-01-07
DE50010060D1 (de) 2005-05-19
PT1244641E (pt) 2005-08-31
BR0017030B8 (pt) 2021-05-25
PL356484A1 (en) 2004-06-28
ATE293104T1 (de) 2005-04-15
EP1244641B1 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
DOP2000000109A (es) Derivados de tiazolilamida
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
UY27098A1 (es) Derivados de indol
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
ES2086313T3 (es) Nuevos derivados de xantina con efecto antagonista de adenosina.
BR0015254B1 (pt) compostos derivados de carbamoiloxialquil-azàlio, seu uso, bem como composiÇço farmacÊutica compreendendo os mesmos.
ECSP077259A (es) Derivados de pirimidina
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BRPI9914571B8 (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
ECSP045271A (es) Derivados de quinolina
ECSP003843A (es) Derivados de tiazolilamida
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
UY26250A1 (es) Sulfonamidas sustituidas con naftilo
UY26435A1 (es) Compuestos bis-básicos como inhibidores de triptasa, procedimiento para su preparación y su utilización como medicamentos.
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
UY27200A1 (es) Derivados de difenilo
DOP2002000352A (es) Derivados de difenilo.
UY26979A1 (es) Nuevos derivados de piranosido
HN2002000052A (es) Derivados de difenilo
ECSP972189A (es) Nuevas triazolopurinas, procedimientos para su preparacion y su empleo como medicamentos
MXPA04001849A (es) Sistemas de indan-1-ol c2-disustituidos, metodo para su produccion y su uso como medicamentos.
MXPA04001846A (es) Indan-1-onas c2-substituidas y sus derivados, metodos para su produccion y su uso como medicamentos.